The U.S. Food and Drug Administration is placing new warnings on popular weight-loss shots, such as Ozambic and Mongro, after monitoring their possible link to an increased risk of developing a rare condition that can lead to sudden vision loss.

The U.S. Food and Drug Administration is placing new warnings on popular weight-loss shots, such as Ozambic and Mongro, after monitoring their possible link to an increased risk of developing a rare condition that can lead to sudden vision loss.

The warning includes all GLP-1 drugs, after cases of non-arterial anterior ischemic optic neuropathy, which is a condition resulting from reduced blood flow to the optic nerve and can cause permanent vision loss, have been documented.